^
    Back
    Association details:
    Biomarker:PD-L1 negative + TMB-L + STING overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2023
    Title:

    Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).

    Published date:
    05/25/2023
    Excerpt:
    Here we report the role of CGS pathway in NSCLC tumors that are both PDL1-negative and TMB-Low....Median overall survival (OS) was 21.1 months in the STING-high cohort (n=200) vs 11.9 months in the STING-low cohort (n=199) in IO treated pts (HR = 0.62, p<0.000.1)
    DOI:
    10.1200/JCO.2023.41.16_suppl.9120